EUVIMEDEUVIMED entdecken
Crossref

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study

Dhruv Ahuja, Kuan-Hung Yeh, Sagar B Patel, Soo-Kyung Park, Ronghui Xu, Siddharth Singh iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Dhruv Ahuja und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Tuberculosis, Biological Products. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Crohn's and Colitis Foundation of America, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a USA claims‐based cohort study in 20,705 patients with inflammatory bowel diseases (IBD) on advanced therapies to estimate the overall and comparative risk of tuberculosis between advanced therapies using inverse probability of treatment weighted Cox proportional hazards model. The incidence rate (IR, per 100,000 person‐years) of tuberculosis with TNF antagonists ( n = 9378) and non‐TNF‐targeting biologics (anti‐integrins [ n = 5877], anti‐interleukins [ n = 5450]) was similar (38 [95% CI, 8–69] vs. 33[7–59]). Adjusting for covariates, risk of tuberculosis was similar (HR, 1.16 [0.41–3.31]). In low incidence regions like USA, the incidence of tuberculosis after starting advanced therapies for IBD is very low, and comparable across advanced therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesTuberculosisBiological ProductsHumansUnited StatesFemaleMaleAdultIncidenceMiddle AgedCohort StudiesProportional Hazards ModelsRisk FactorsTumor Necrosis Factor-alphaYoung AdultAged

Stichwörter der Autor:innen

infliximablatent tuberculosisopportunistic infectionsustekinumabvedolizumab

Substanzen

Biological ProductsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Department of Medicine, Indira Gandhi Hospital, New Delhi, India.
  • Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Division of Gastroenterology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic-Arizona, Scottsdale, Arizona, USA.

ORCID-Profile: Siddharth Singh

Förderung

  • Crohn's and Colitis Foundation of America
  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ahuja, D., Yeh, K. H., Patel, S. B., Park, S. K., Xu, R., & Singh, S. (2025). Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70443

Vancouver

Ahuja D, Yeh KH, Patel SB, Park SK, Xu R, Singh S. Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70443

BibTeX
@article{Ahuja2025,
  author = {Ahuja, Dhruv and Yeh, Kuan-Hung and Patel, Sagar B and Park, Soo-Kyung and Xu, Ronghui and Singh, Siddharth},
  title = {Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70443}
}
Kostenlos starten →